Longeveron Secures Canadian Patent For LOMECEL-B Use In Treating Aging Frailty And Non-Ischemic Dilated Cardiomyopathy, Secures Protection Until 2037

Longeveron Inc., a clinical-stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and age-related conditions, has announced that the Canadian Intellectual Property Office (CIPO) has granted a patent related to the use of its investigational product laromestrocel (LOMECEL-B). The patent covers the administration of the company’s proprietary mesenchymal stem cells (MSCs) for treating patients with symptoms of aging-related frailty as well as those diagnosed with non-ischemic dilated cardiomyopathy (NIDCM).

The newly issued Canadian Patent No. 3043594, titled “Method of Using Human Mesenchymal Stem Cells to Effect Cellular and Humoral Immunity,” provides Longeveron with patent protection in Canada until 2037. This strengthens the company’s intellectual property position as it continues to advance its cell therapy programs. Aging-related frailty is a clinical syndrome commonly seen in older adults and is characterized by a decline across multiple physiological systems. Individuals with this condition often experience reduced strength, lower physical activity, slower motor function, persistent tiredness, and unintended weight loss. Numerous studies have connected aging-related frailty to chronic inflammation. 

The concept of “inflammaging” has become increasingly important, suggesting that immune system changes over time may contribute to various age-associated diseases and conditions. Longeveron has previously completed Phase 1 and Phase 2 trials evaluating laromestrocel in individuals with aging-related frailty. These studies were designed to assess improvements in functional measures, including the six-minute walk test, along with overall physical performance.

The patent also covers the use of laromestrocel for non-ischemic dilated cardiomyopathy, a condition in which the heart muscle enlarges and weakens, reducing its ability to pump blood effectively. NIDCM is a progressive disorder with no cure and often leads to the need for a heart transplant. Research has shown that administering isolated MSCs can positively impact immune markers commonly elevated during chronic inflammation, which may be clinically relevant for patients at higher risk of co-morbid infections.

Laromestrocel is a living cell therapy derived from mesenchymal stem cells obtained from the bone marrow of healthy young adult donors. These cells play a crucial role in the body’s natural repair processes and are capable of supporting tissue regeneration. They are known to migrate to areas of injury or disease and release bioactive factors that help regulate immune responses and promote healing. Due to these properties, Longeveron believes laromestrocel may provide anti-inflammatory and regenerative benefits and could potentially be used to address a broad range of rare and age-related disorders.